/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

HOOKIPA Pharma Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.83 -0.0692(-6.92%) HOOK at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 0.8701
Highest Today 0.92
Today’s Open 0.9027
Prev. Close 0.9028
52 Week High 5.66
52 Week Low 0.72
Day’s Range: Low 0.8701 High 0.92
52-Week Range: Low 0.72 High 5.66
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -43.08
1 year return -64.31
3 year return -9.41
5 year return -92.22
10 year return -

Institutional Holdings

Baker Bros Advisors LP 6.67

Siren, L.L.C. 4.65

FMR Inc 2.87

Vanguard Group Inc 2.47

Vanguard Total Stock Mkt Idx Inv 1.87

Fidelity VIP Growth Initial 0.83

Fidelity Capital Appreciation 0.75

Geode Capital Management, LLC 0.60

Vanguard Institutional Extnd Mkt Idx Tr 0.57

Fidelity Advisor Equity Growth I 0.55

Acadian Asset Management LLC 0.46

Ikarian Capital, LLC 0.43

Fidelity Growth Discovery 0.37

Renaissance Technologies Corp 0.34

Squarepoint Ops LLC 0.33

Fidelity Extended Market Index 0.32

UBS Group AG 0.25

Prudential Financial Inc 0.24

Dimensional Fund Advisors, Inc. 0.23

Royal Bank of Canada 0.19

Susquehanna International Group, LLP 0.16

Morgan Stanley - Brokerage Accounts 0.14

State Street Corp 0.14

XTX Topco Ltd 0.13

Northern Trust Corp 0.13

Fidelity Advisor Series Equity Gr 0.11

BlackRock Inc 0.10

BOOTHBAY FUND MANAGEMENT, LLC 0.10

Fidelity Total Market Index 0.09

Fidelity Series Total Market Index 0.08

Pacific Select Large-Cap Growth I 0.07

NT Ext Equity Mkt Idx Fd - NL 0.07

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Spartan Total Market Index Pool G 0.05

Extended Equity Market Fund K 0.04

Spartan Extended Market Index Pool F 0.03

Fidelity Nasdaq Composite Index 0.03

Fidelity VIP Dynamic Cap App Initial 0.03

Market Status

Strong Buy: 1

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 11.22 M

PB Ratio 0.3231

PE Ratio 0.0

Enterprise Value -28.67 M

Total Assets 82.55 M

Volume 333986

Company Financials

Annual Revenue FY23:20550000 20.6M, FY22:14249000 14.2M, FY21:18448000 18.4M, FY20:19584000 19.6M, FY19:11942000 11.9M

Annual Profit FY23:null 0.0M, FY22:14249000 14.2M, FY21:18448000 18.4M, FY20:19584000 19.6M, FY19:11942000 11.9M

Annual Net worth FY23:-69073000 -69.1M, FY22:-65145000 -65.1M, FY21:-75666000 -75.7M, FY20:-33801000 -33.8M, FY19:-34147000 -34.1M

Quarterly Revenue Q1/2025:2004000 2.0M, Q3/2024:4703000 4.7M, Q2/2024:1290000 1.3M, Q1/2024:36599000 36.6M, Q4/2023:7407000 7.4M

Quarterly Profit Q1/2025:2004000 2.0M, Q3/2024:4703000 4.7M, Q2/2024:1134000 1.1M, Q1/2024:35959000 36.0M, Q4/2023:6129000 6.1M

Quarterly Net worth Q1/2025:-15427000 -15.4M, Q3/2024:-13841000 -13.8M, Q2/2024:-19095000 -19.1M, Q1/2024:14383000 14.4M, Q4/2023:-24818000 -24.8M

Fund house & investment objective

Company Information HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 82

Industry Biotechnology

CEO Dr. Malte Peters M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow